Souhaitez-vous accéder aux communiqués récents ?

AUSTIN, Texas, Dec. 02, 2025 (GLOBE NEWSWIRE) -- BioMedWire: Chronic conditions and rare diseases in the aging population present an urgent and expanding challenge within the U.S. healthcare system,...

The collaboration unites complementary scientific and technical expertise to provide seamless solutions across the biopharmaceutical value chainClients to benefit from accelerated timelines, as well...

InnoCare's pipeline under development now covers ten major autoimmune diseases, with a particular focus on dermatological conditions.

First publicly listed company to actively investigate psilocybin’s potential impact on longevity NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed”...

AUSTIN, Texas, Nov. 24, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: As advanced biotech programs move closer to commercialization, fair-value adjustments under U.S. Generally Accepted...

Curium and CapVest have announced the recapitalization of Curium via a new Continuation Vehicle The transaction values Curium at circa $7 billion, representing the largest transaction in nuclear...

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...

Curium Biopharma will continue to lead discovery and new product development Strategic move aims to accelerate biopharma innovation and revolutionize the diagnosis and treatment of cancerCurium...

Kneat's market leadership continues, with Q3 2025 YoY growth in ARR of 37% to $68.6 million and in SaaS revenue of 33% to $15.2 million.

CHASKA, Minn, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today...